National Burden of Preventable Adverse Drug Events Associated with Inpatient Injectable Medications: Healthcare and Medical Professional Liability Costs
Betsy J Lahue, MPH, Bruce Pyenson, FSA, MAAA, Kosuke Iwasaki, FIAJ, MAAA, Helen Blumen, MD, MBA, Susan Forray, FCAS, MAAA, Jeffrey M. Rothschild, MD, MPH
Preventable medication errors have emerged as a prominent cost and quality issue in the United States, and are estimated to impact more than 7 million patients, contribute to 7000 deaths, and cost almost $21 billion in direct medical costs across all care settings annually.1,2 Adverse drug events (ADEs) are harms that result from medication use; when these harms result from a medication error, they are known as “preventable ADEs.”3 The inpatient hospital setting is particularly resource-intensive in terms of care delivered and exposure to potential harms a
Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study
Barbara Lennert, RN, BSN, MAOM, Wendy Bibeau, PhD, Eileen Farrelly, MPH, Patricia Sacco, MPH, RPh, Tessa Schoor, MD
Parkinson’s disease is a degenerative disorder that is characterized by muscle rigidity, tremors, and motor impairment that often results in progressive disability and severe complications that seriously affect a patient’s health-related quality of life (QOL) and physical functioning.
Parkinson’s Disease: A Complicated but Underappreciated and Undertreated Condition
Aarti A. Patel, PharmD, MBA, Barbara Lennert, RN, BSN, MAOM, Brian Macomson, PharmD, Winnie W. Nelson, PharmD, Gary M. Owens, MD, Samir H. Mody, PharmD, MBA, Jeff Schein, DrPH, MPH
Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia, diagnosed in approximately 1% of the general population.1 It is estimated that AF currently affects more than 2 million people in the United States and more than 4 million across the European Union, with the number of US patients with AF estimated to increase 2.5-fold by the year 2050.1,2
The Enormous Impact of Atrial Fibrillation and Stroke on Patients, Payers, and Society
Conceptual and Analytical Considerations toward the Use of Patient-Reported Outcomes in Personalized Medicine
Personalized medicine aims to assist healthcare providers to individualize a patient treatment based on the patient’s attributes, which may include biomarkers, genetics, demographic characteristics, and other covariates. Much progress has been made in recent years in the translational research areas of genomics, proteomics, and metabolomics, and several biomarkers have been identified for a number of important diseases, including atherosclerosis, cancer, and rheumatoid arthritis.
No Physician Treats an Average Patient: Bridging the Gap between Group-Based Data and Patient-Specific Treatment Outcomes
Nausea and vomiting are 2 serious and related side effects of cancer chemotherapy. These adverse effects can cause significant negative impacts on patients’ quality of life and on their ability to comply with therapy. Also, nausea and vomiting can result in anorexia, decreased performance status, metabolic imbalance, wound dehiscence, esophageal tears, and nutritional deficiency.1,2 Despite advances in the prevention and management of chemotherapy-induced nausea and vomiting (CINV), these side effects remain among the most distressing for patients.
Selecting Best Therapies for Control of Chemotherapy-Induced Nausea and Vomiting
Lindsay Sanders, DO, MPH, Anu P. Michael, MD, Scott R. Anderson, MS IV, Loida D. Nguyen, PharmD, BCPS, Zackary A. Johnson, MS II, Quang T. Nguyen, DO, FACP, FACE, FTOS
Scott R. Anderson, MS IV, Lindsay Sanders, DO, MPH, Loida D. Nguyen, PharmD, BCPS, Quang T. Nguyen, DO, FACP, FACE, FTOS
Hypertension, defined as systolic blood pressure (BP) ≥140 mm Hg, diastolic BP ≥90 mm Hg, increases with age, affecting more than 50% of patients aged ≥60 years, and approximately 66% of those aged ≥65 years.1-3 It is well known that by 2030, 1 of 5 Americans is expected to be 65 years or older.
Improving Hypertension Management in the Elderly a Core Clinical Goal
Benefits of Novel Oral Anticoagulant Agents for Thromboprophylaxis after Total Hip or Knee Arthroplasty
Total hip arthroplasty (THA) and total knee arthroplasty (TKA) are among the most common orthopedic procedures performed in the United States, with almost 300,000 THA surgeries and more than 500,000 TKA surgeries performed annually.1 This number is projected to rise to approximately 572,000 annual THA surgeries and 3.5 million annual TKA surgeries by 2030.1 THA and TKA procedures improve mobility and quality of life, but patients undergoing these surgeries are at a significantly increased risk for developing postoperative venous thromboembolism (VTE).2-4 VTE
A Paradigm Shift in Anticoagulation?
R. Amy Puenpatom, PhD, Sheryl L. Szeinbach, PhD, RPh, Larry Ma, PhD, Rami H. Ben-Joseph, PhD, Kent H. Summers, PhD, BSPharm
Chronic pain is experienced by more than one third of the US population.1 Regardless of disease etiology or individual characteristics, chronic pain is debilitating and has a profound impact on emotional and physical functioning.2,3 For chronic pain, which is characterized as pain lasting 3 or more months,4 opioid analgesics are considered part of a multifaceted strategy to manage moderate-to-severe pain for a number of conditions involving the musculoskeletal system (eg, osteoarthritis, low back pain), neurologic system (eg, diabetic neuropathy, spinal cord
Daily Average Consumption of 2 Long-Acting Opioids and Coverage Decisions
Brett Pinsky, MPH, James Harnett, PharmD, Ryne Paulose-Ram, PhD, Jack Mardekian, PhD, Navendu Samant, PhD, Kavita V. Nair, PhD
Health plans are increasingly offering payment incentives to motivate providers to strive for improving the quality of patient care based on established criteria such as those set forth by the National Committee for Quality Assurance (NCQA).1,2
What Certification Really Means for Physician Quality
Page 7 of 11
Results 61 - 70 of 107
Results 61 - 70 of 107